The Latest Breaking News from Charles River Laboratories

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

It's unclear if President Trump is just toying around with the threat of tariffs. But it's not fun for large U.S. companies in the S&P 500.

The S&P 500 index is up slightly in 2024, but many components are big losers, including Dow Jones giant Boeing and Tesla.

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for...

Horseshoe crab blood is used to test vaccines around the world. But while Europe has approved a synthetic alternative, biomedical labs are bleeding more crabs from the Atlantic Coast.

Charles River Laboratories announced a shortfall in monkey shipments on Wednesday that weighed on its 2023 outlook, and CRL stock toppled.

The shares of Charles River Laboratories (CRL) have plunged in price despite the company’s solid results. So, can they rebound by the company leveraging its broad portfolio of products and services? Read on. Let’s find out.